Sugi Predict

Sugi Predict / Compounds / SCHEMBL2933292

SCHEMBL2933292

SCHEMBL2933292

CCCCCCCCCC(=O)O[C@]1(C(=O)CO)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 13/20 0.95
▸ PGR P06401 4/20 0.95
▸ CYP3A4 P08684 4/20 0.95
▸ USP2 O75604 3/20 0.95
▸ MEN1 O00255 1/20 0.95
▸ KMT2A Q03164 1/20 0.95
▸ MMP1 P03956 10/20 0.79
▸ LMNA P02545 2/20 0.72
▸ NR1I2 O75469 2/20 0.72
▸ MAPT P10636 2/20 0.72
▸ MLNR O43193 1/20 0.72
▸ ABCB11 O95342 1/20 0.72
▸ CYP3A5 P20815 1/20 0.72
▸ PPARG P37231 1/20 0.72
▸ SMN1; SMN2 Q16637 1/20 0.72
▸ NPSR1 Q6W5P4 1/20 0.72
▸ CYP2D6 P10635 1/20 0.72
▸ CYP2C9 P11712 1/20 0.72
▸ ADORA3 P0DMS8 1/20 0.71
▸ DRD2 P14416 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151466 1.00 NR3C1 (0.95) NR3C1PGRCYP3A4USP2MEN1
SCHEMBL2933726 1.00 NR3C1 (0.95) NR3C1PGRCYP3A4USP2MEN1
SCHEMBL2940259 1.00 NR3C1 (0.95) NR3C1PGRCYP3A4USP2MEN1
SCHEMBL93888 1.00 NR3C1 (0.95) NR3C1PGRCYP3A4USP2MEN1
Betamethasone Valerate SCHEMBL14339607 0.98 NR3C1 (1.00) NR3C1PGRCYP3A4USP2MEN1
Betamethasone Valerate SCHEMBL16243364 0.98 NR3C1 (1.00) NR3C1PGRCYP3A4USP2MEN1
Betamethasone Valerate SCHEMBL9768484 0.98 NR3C1 (1.00) NR3C1PGRCYP3A4USP2MEN1
Betamethasone Valerate SCHEMBL11051241 0.98 NR3C1 (1.00) NR3C1PGRCYP3A4USP2MEN1
Dexamethasone Valarate SCHEMBL124723 0.98 NR3C1 (1.00) NR3C1PGRCYP3A4USP2MEN1
Betamethasone Valerate SCHEMBL14339612 0.98 NR3C1 (1.00) NR3C1PGRCYP3A4USP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230320979-A1 OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION SANTEN SAS (FR) 2023-10-12 — — US claimed
EP-4213804-A1 OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION Santen SAS (FR) 2023-07-26 — — EP claimed
WO-2022058325-A1 OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION SANTEN SAS (FR) 2022-03-24 — — WO claimed
US-8623852-B2 Topical methods and compositions for the treatment of eye diseases and conditions SANTEN SAS (FR) 2014-01-07 — — US claimed
EP-2564853-A1 Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders Novagali Pharma S.A. (FR) 2013-03-06 — — EP claimed
US-20100286065-A1 TOPICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES AND CONDITIONS NOVAGALI PHARMA SA (FR) 2010-11-11 — — US claimed
EP-2229174-A1 COMPOSITIONS COMPRISING CORTICOSTEROID PRODRUG SUCH AS DEXAMETHASONE PALMITATE FOR THE TREATMENT OF EYE DISORDERS Novagali Pharma S.A. (FR) 2010-09-22 — — EP claimed
WO-2009071594-A1 COMPOSITIONS COMPRISING CORTICOSTEROID PRODRUG SUCH AS DEXAMETHASONE PALMITATE FOR THE TREATMENT OF EYE DISORDERS NOVAGALI PHARMA SA (FR) 2009-06-11 — — WO claimed
US-20240156960-A1 SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT DNARx (US) 2024-05-16 — — US disclosed
US-20230320979-A1 OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION SANTEN SAS (FR) 2023-10-12 — — US disclosed
EP-4216935-A1 SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT Dnarx (US) 2023-08-02 — — EP disclosed
EP-4213804-A1 OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION Santen SAS (FR) 2023-07-26 — — EP disclosed
US-20230212610-A1 NUCLEIC ACID EXPRESSION USING SUBCUTANEOUS ADMINISTRATION DNARx (US) 2023-07-06 — — US disclosed
WO-2023122535-A2 NUCLEIC ACID EXPRESSION USING SUBCUTANEOUS ADMINISTRATION DNARx (US) 2023-06-29 — — WO disclosed
WO-2022058325-A1 OIL-IN-WATER EMULSIONS FOR INTRAVITREAL ADMINISTRATION SANTEN SAS (FR) 2022-03-24 — — WO disclosed
US-8623852-B2 Topical methods and compositions for the treatment of eye diseases and conditions SANTEN SAS (FR) 2014-01-07 — — US disclosed
EP-2564853-A1 Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders Novagali Pharma S.A. (FR) 2013-03-06 — — EP disclosed
US-20100286065-A1 TOPICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES AND CONDITIONS NOVAGALI PHARMA SA (FR) 2010-11-11 — — US disclosed
EP-2229174-A1 COMPOSITIONS COMPRISING CORTICOSTEROID PRODRUG SUCH AS DEXAMETHASONE PALMITATE FOR THE TREATMENT OF EYE DISORDERS Novagali Pharma S.A. (FR) 2010-09-22 — — EP disclosed
WO-2009071594-A1 COMPOSITIONS COMPRISING CORTICOSTEROID PRODRUG SUCH AS DEXAMETHASONE PALMITATE FOR THE TREATMENT OF EYE DISORDERS NOVAGALI PHARMA SA (FR) 2009-06-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156960-A1 SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT ACE2, ACE, IGF2BP2 NR3C1 312/4885PGR 287/4885CYP3A4 4808/4885
US-20230212610-A1 NUCLEIC ACID EXPRESSION USING SUBCUTANEOUS ADMINISTRATION FABP4, APMAP, IGF2BP2 NR3C1 1388/4885PGR 1557/4885CYP3A4 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.